These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18414967)

  • 21. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study.
    Bingham CO; Ince A; Haraoui B; Keystone EC; Chon Y; Baumgartner S
    Curr Med Res Opin; 2009 May; 25(5):1131-42. PubMed ID: 19317607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.
    Ariza-Ariza R; Navarro-Sarabia F; Hernández-Cruz B; Rodríguez-Arboleya L; Navarro-Compán V; Toyos J
    Rheumatology (Oxford); 2007 Mar; 46(3):529-32. PubMed ID: 17012439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
    Geborek P; Crnkic M; Petersson IF; Saxne T;
    Ann Rheum Dis; 2002 Sep; 61(9):793-8. PubMed ID: 12176803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab.
    Matsuno H
    Mod Rheumatol; 2010 Dec; 20(6):561-5. PubMed ID: 20552246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.
    van Vollenhoven R; Harju A; Brannemark S; Klareskog L
    Ann Rheum Dis; 2003 Dec; 62(12):1195-8. PubMed ID: 14644858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment patterns of anti-TNF agents in Italy: an observational study.
    Punzi L; Matucci Cerinic M; Cantini F; Bagnato G; Fiocco U; Ferri C; Bombardieri S
    Reumatismo; 2011 Mar; 63(1):18-28. PubMed ID: 21509346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.
    Furst DE; Gaylis N; Bray V; Olech E; Yocum D; Ritter J; Weisman M; Wallace DJ; Crues J; Khanna D; Eckel G; Yeilding N; Callegari P; Visvanathan S; Rojas J; Hegedus R; George L; Mamun K; Gilmer K; Troum O
    Ann Rheum Dis; 2007 Jul; 66(7):893-9. PubMed ID: 17412737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.
    Giardina AR; Ferrante A; Ciccia F; Impastato R; Miceli MC; Principato A; Triolo G
    Rheumatol Int; 2010 Sep; 30(11):1437-40. PubMed ID: 19851772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A; Simard JF; Gabay C; Guerne PA;
    Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission.
    Miyamura T; Sonomoto K; Nakamura M; Horai Y; Takahama S; Ando H; Minami R; Yamamoto M; Suematsu E
    Clin Rheumatol; 2010 Jan; 29(1):87-90. PubMed ID: 19756835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.
    Finckh A; Simard JF; Duryea J; Liang MH; Huang J; Daneel S; Forster A; Gabay C; Guerne PA
    Arthritis Rheum; 2006 Jan; 54(1):54-9. PubMed ID: 16385495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
    Bacquet-Deschryver H; Jouen F; Quillard M; Ménard JF; Goëb V; Lequerré T; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumor necrosis factor therapies.
    Taylor PC
    Curr Opin Rheumatol; 2001 May; 13(3):164-9. PubMed ID: 11333343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
    Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
    Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study.
    Wakabayashi H; Hasegawa M; Nishioka Y; Sudo A; Nishioka K
    Mod Rheumatol; 2012 Feb; 22(1):116-21. PubMed ID: 21710357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.
    Mikuls TR; Moreland LW
    Expert Opin Pharmacother; 2001 Jan; 2(1):75-84. PubMed ID: 11336570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and Its soluble receptors during the course of therapy with etanercept and infliximab.
    Schulz M; Dotzlaw H; Neeck G
    Biomed Res Int; 2014; 2014():675108. PubMed ID: 24783218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.